denileukin diftitox

Home
Ligands
denileukin diftitox

GtoPdb Ligand ID: 7044

Synonyms: DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak®

denileukin diftitox is an approved drug (FDA (1999))

Comment: Denileukin diftitox is an anti-cancer immunotherapy drug that was designed to target and eradicate malignant (IL-2 receptor-expressing) T cells. It is a recombinant protein containing peptide sequences of both interleukin-2 and diphtheria toxin [1,5]. It simultaneously directly kills IL-2R expressing tumour cells and promotes depletion of host Treg cells which enhances the immune response

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

Bioactivity Comments
We have been unable to find publicly available affinity data for this drug at its proposed molecular target, in this case the IL-2R, to substantiate its MMOA, and have therefore not tagged a primary drug target.

Bioactivity Comments

We have been unable to find publicly available affinity data for this drug at its proposed molecular target, in this case the IL-2R, to substantiate its MMOA, and have therefore not tagged a primary drug target.